What's in Lumara Health, Inc.'s pipeline?

Lumara Health, Inc. has 8 drugs in our index: 0 marketed, 0 filed, 6 in Phase 3, 2 in Phase 2, 0 in Phase 1.

Which companies overlap with Lumara Health, Inc.'s portfolio?

Top competitors by shared drug class: AstraZeneca, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh, Dharmais National Cancer Center Hospital, Eastern Virginia Medical School, Genor Biopharma Co., Ltd..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/lumara-health-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Lumara Health, Inc. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Lumara Health, Inc. pipeline: 0 marketed, 0 filed, 6 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 6 Phase 3 2 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Placebo transdermal two 90 μL sprays	Placebo transdermal two 90 μL sprays	phase 3
clindamycin phosphate/butoconazole nitrate	clindamycin phosphate/butoconazole nitrate	phase 3	Antibiotic and antifungal combination		Fungal infections, Bacterial infections
Estradiol transdermal three 90 μL sprays	Estradiol transdermal three 90 μL sprays	phase 3	Hormone replacement therapy (HRT); estrogen	Estrogen receptor alpha (ERα), Estrogen receptor beta (ERβ)	Endocrinology / Women's Health
Placebo transdermal one 90 μL spray	Placebo transdermal one 90 μL spray	phase 3
Estradiol transdermal one 90 μL spray	Estradiol transdermal one 90 μL spray	phase 3	Hormone replacement therapy (HRT) / Estrogen	Estrogen receptor alpha (ERα), Estrogen receptor beta (ERβ)	Endocrinology / Women's Health
Placebo transdermal three 90 μL sprays	Placebo transdermal three 90 μL sprays	phase 3

Therapeutic area mix

Endocrinology / Women's Health · 2
Fungal infections, Bacterial infections · 1
Hematology; Immunology; Gynecology · 1
Oncology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

AstraZeneca · 1 shared drug class
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh · 1 shared drug class
Dharmais National Cancer Center Hospital · 1 shared drug class
Eastern Virginia Medical School · 1 shared drug class
Genor Biopharma Co., Ltd. · 1 shared drug class
Gynaecologisch Oncologisch Centrum Zuid · 1 shared drug class
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy · 1 shared drug class
Amgen · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Lumara Health, Inc.:

Cite this brief

Drug Landscape (2026). Lumara Health, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/lumara-health-inc. Accessed 2026-05-17.